Ozempic vs Saxenda: Switching Between Them Safely At a glance Drug class / Both are GLP-1 receptor agonists acting on the same receptor Ozempic dosing / Once-weekly subcutaneous injection, 0.25 mg titrated to 0.5, 1.0, or 2.0 mg Saxenda dosing / Once-daily subcutaneous injection, titrated from 0.6 mg to 3.0 mg over 4-5 weeks SUSTAIN-7 weight loss / Semaglutide 1.0 mg produced 5.5-7.3 kg loss at 40 weeks in type 2 diabetes SCALE trial weight loss / Liraglutide 3.0 mg produced 8.0% mean body weight loss at 56 weeks FDA indication for Ozempic / Type 2 diabetes (weight loss is off-label at current doses) FDA indication for Saxenda / Chronic weight management in adults with BMI 30 or 27 with comorbidity Switching protocol / Stop one agent, begin the new agent at the lowest titration dose Common switch reason / GI intolerance, insufficient efficacy, or insurance coverage changes No washout required / Both drugs target the GLP-1 receptor, so no washout period is needed before switching How Ozempic and Saxenda Compare Head to Head Both Ozempic and Saxenda activate the GLP-1 receptor, but they are different molecules with distinct pharmacokinetic profiles

Innovative approach We have the backing of scientific endorsements and clinical studies.
A type of circulation problem can worsen or happen after receiving EMGALITY
Table of Contents Nights 1-3: Initial Response Days 4-7: Sleep Architecture Shifts Weeks 2-3: Cumulative Benefits Weeks 3-4: Peak Cycle Benefits After Cycle Completion: Off-Period Factors That Affect Results By Use Case: Different Timelines When to Adjust Protocol Related Reading References Nights 1-3: Initial Response DSIP produces effects faster than most people expect for a peptide
Patients with previous bowel resections face heightened risk, as they may already have compromised absorptive capacity